Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (also referred to as Newcelx Ltd. in metadata) is dated October 11, 2024. The report addresses the company's status regarding Nasdaq listing compliance following a notification of non-compliance with the minimum stockholders' equity requirement.
Key Financial Metrics
The filing does not provide a comprehensive income statement, balance sheet, or cash flow statement. However, it discloses specific capital activity:
- Net Proceeds from Securities Sales: Approximately $3.2 million.
- Stockholders' Equity: The company states it now satisfies the minimum requirement of $2.5 million.
- Debt: Certain debt was exchanged for preferred stock, though the specific principal amount is not quantified in this text.
Material Changes
Since the fiscal year ended December 31, 2023, the company has taken corrective actions to address a deficiency in stockholders' equity under Nasdaq Listing Rule 5550(b). The primary changes include raising capital through the sale of securities and converting existing debt obligations into preferred equity. These actions have restored the company's compliance with the $2.5 million equity threshold.
Outlook and Management Commentary
Management, represented by CEO Alexander Zwyer, confirms that the company believes it currently satisfies the stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The filing notes that this report is incorporated by reference into the company's active Registration Statements on Form F-3.
Investor Verification Checklist
- Verify the exact date the $2.5 million stockholders' equity threshold was met.
- Confirm the specific terms and valuation of the preferred stock issued in the debt-for-equity exchange.
- Review the latest audited financial statements to validate the current equity balance and debt levels.
- Check for any subsequent correspondence from Nasdaq confirming the restoration of compliance.